Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWang, Mengzhao-
dc.contributor.authorYang, James Chih-Hsin-
dc.contributor.authorMitchell, Paul L R-
dc.contributor.authorFang, Jian-
dc.contributor.authorCamidge, D Ross-
dc.contributor.authorNian, Weiqi-
dc.contributor.authorChiu, Chao-Hua-
dc.contributor.authorZhou, Jianying-
dc.contributor.authorZhao, Yanqiu-
dc.contributor.authorSu, Wu-Chou-
dc.contributor.authorYang, Tsung-Ying-
dc.contributor.authorZhu, Viola W-
dc.contributor.authorMillward, Michael-
dc.contributor.authorFan, Yun-
dc.contributor.authorHuang, Wen-Tsung-
dc.contributor.authorCheng, Ying-
dc.contributor.authorJiang, Liyan-
dc.contributor.authorBrungs, Daniel-
dc.contributor.authorBazhenova, Lyudmila-
dc.contributor.authorLee, Chee Khoon-
dc.contributor.authorGao, Bo-
dc.contributor.authorXu, Yan-
dc.contributor.authorHsu, Wei-Hsun-
dc.contributor.authorZheng, Li-
dc.contributor.authorJanne, Pasi A-
dc.identifier.citationCancer Discovery 2022; 12(7): 1676-1689en
dc.description.abstractEpidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to lack of effective therapy, the prognosis of these patients was poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible and selective EGFR tyrosine kinase inhibitor, showing activity against EGFR exon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase 1 clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFR exon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response (DoR) has not been reached.en
dc.titleSunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer Discoveryen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationWestmead Hospital, Australiaen
dc.identifier.affiliationSir Charles Gairdner Hospital, Perth, WA, Australiaen
dc.identifier.affiliationMedical Day Care Centre, Australiaen
dc.identifier.affiliationPeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen
dc.identifier.affiliationUniversity of Sydney, Sydney, New South Wales, Australiaen
dc.identifier.affiliationNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwanen
dc.identifier.affiliationPeking University Cancer Hospital and Institute, Beijing, Chinaen
dc.identifier.affiliationUniversity of Colorado Cancer Center, Aurora, Colorado, United Statesen
dc.identifier.affiliationChongqing University Cancer Hospital, chongqing, Chinaen
dc.identifier.affiliationTaipei Veterans General Hospital, Taipei, Taiwanen
dc.identifier.affiliationFirst Affiliated Hospital Zhejiang University, Hangzhou, Chinaen
dc.identifier.affiliationAffiliated Cancer Hospital of Zhengzhou University, Chinaen
dc.identifier.affiliationNational Cheng Kung University Hospital, Tainan, Taiwanen
dc.identifier.affiliationNational Yang Ming University, Taipei, Taiwan, Taiwanen
dc.identifier.affiliationUniversity of California, Irvine, Orange, CA, United Statesen
dc.identifier.affiliationZhejiang Cancer Hospital, Hangzhou, Zhejiang, Chinaen
dc.identifier.affiliationChiMei medical center, liouying, Tainan, Taiwanen
dc.identifier.affiliationJilin Provincial Cancer Hospital, Changchun, Chinaen
dc.identifier.affiliationShanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Chinaen
dc.identifier.affiliationUC San Diego Moores Cancer Center, La Jolla, CA, United Statesen
dc.identifier.affiliationPeking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chinaen
dc.identifier.affiliationNational Taiwan University Hospital, Taipei, Taiwanen
dc.identifier.affiliationDizal pharmaceuticals, Shanghai, Chinaen
dc.identifier.affiliationDana-Farber Cancer Institute, Boston, Massachusetts, United Statesen
dc.identifier.pubmedid35404393-, Paul L R
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristype Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 24, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.